Lotus Pharmaceuticals : Informational Disclosure

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

8551 Lamar Court

North Port, FL 34287

941-257-9684

[e-mail]

Quarterly Report

For the Period Ending: September 30, 2021

(the "Reporting Period")

As of September 30, 2021, the number of shares outstanding of our Common Stock was:

2,944,515,543

As of June 30, 2021, the number of shares outstanding of our Common Stock was:

2,944,515,543

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

2,994,515,543

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting period:

Yes: ☐

No: ☒

1 "Change in Control" shall mean any events resulting in:

1. Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
2. The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
3. A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
4. The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3.1 June 24, 2021)	Page 1 of 9

1. Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The Company was incorporated in the State of Nevada on January 28, 2004 under the name S.E. Asia Trading, Inc. On December 6, 2006, the Company changed its name to Lotus Pharmaceuticals, Inc. The Company's address is 8551 Lamar Court, North Port, FL 34287

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was incorporated in the State of Nevada on January 28, 2004 under the name S.E. Asia Trading, Inc. On August 28, 2006, Lotus International, Inc. was incorporated in the State of Nevada. On September 6, 2006, a Share Exchange Agreement was entered into between the Company and Lotus International, Inc., with Lotus International, Inc. becoming a wholly owned subsidiary of the Company on September 28, 2006. Finally, on December 6, 2006, the Company changed its name to Lotus Pharmaceuticals, Inc. The Company is in active status with the State of Nevada.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

8551 Lamar Court

North Port, FL 34287

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☒

No: ☐

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

On December 22, 2015, a lawsuit was filed against Lotus Pharmaceuticals, Inc. in the District Court of Clark County, Nevada, entitled "In the Matter of Favored, Inc." under case number A-16-+744110-C by a Shareholder, Barton Hollow, LLC, along with an Application for Appointment of Custodian, after several attempts to locate prior management and reinstate the Company's Nevada charter, which had been revoked.

On November 14, 2016, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of Barton Hollow, LLC as Custodian of Lotus Pharmaceuticals, Inc. Barton Hollow, LLC (the "Custodian") is an entity controlled by securities attorney Adam S. Tracy, its Managing Member.

On November 16, 2016, by resolution of Barton Hollow, LLC, Custodian caused 60,000,000 restricted common shares to be issued to Barton Hollow LLC as consideration for Barton Hollow satisfying the outstanding obligations of the Company.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3.1 June 24, 2021)	Page 2 of 9

2)	Security Information
Trading symbol:	LTUS
Exact title and class of securities outstanding:	Common Stock
CUSIP:		545715 203
Par or stated value:	$0.001
Total shares authorized:	3,000,000,000	as of date: September 30, 2021
Total shares outstanding:	2,944,515,543	as of date: September 30, 2021
Number of shares in the Public Float2:	263,351,573	as of date: September 30, 2021
Total number of shareholders of record:	51	as of date: September 30, 2021

All additional class(es) of publicly traded securities (if any):

Trading symbol:	N/A
Exact title and class of securities outstanding:
CUSIP:
Par or stated value:
Total shares authorized:		as of date:
Total shares outstanding:		as of date:
Transfer Agent
Name:	Signature Stock Transfer
Phone:	972-812-4120
Email:	[e-mail]
Address:	14673 Midway Road
	Suite 220
	Addison, TX 75001
Is the Transfer Agent registered under the Exchange Act?3 Yes: ☒	No: ☐

1. Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

1. "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.
2. To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3.1 June 24, 2021)	Page 3 of 9

Shares Outstanding as of Second Most Recent

Fiscal Year End:

Opening Balance

*Right-click the rows below and select "Insert" to add rows as needed.

Date 12/31/19

Common: 2.994,515.543

Preferred: -0-

Date of

Transaction

Number of

Class of

Value of

Were the

Individual/ Entity

Reason for share

Restricted or

Exemption

Transaction

type (e.g. new

Shares

Securities

shares

shares

Shares were

issuance (e.g. for

Unrestricted

or

issuance,

Issued (or

issued

issued at

issued to

cash or debt

as of this

Registration

cancellation,

cancelled)

($/per

a discount

(entities must

conversion)

filing.

Type.

shares

share) at

to market

have individual

-OR-

returned to

Issuance

price at

with voting /

Nature of

treasury)

the time

investment

Services

of

control

Provided

issuance?

disclosed).

(Yes/No)

Shares Outstanding

on Date of This

Report:

Ending Balance:

Date 6/30/21

Common: 2,994,515,543

Preferred: -0-

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of	Outstanding	Principal	Interest	Maturity	Conversion Terms (e.g.	Name of Noteholder	Reason for
Note	Balance ($)	Amount	Accrued	Date	pricing mechanism for	(entities must have	Issuance (e.g.
Issuance		at	($)		determining conversion of	individual with voting	Loan, Services,
		Issuance			instrument to shares)	/ investment control	etc.)
		($)				disclosed).
12/31/19	$57,274	$30,369	-0-	Demand	N/A	Georgene Rivers	Loan (1)

Use the space below to provide any additional details, including footnotes to the table above:

1. This obligation is not represented by a promissory note and is reflected in the financial statements as a loan from shareholder. The outstanding balance reflects advances made to Company by Georgene Rivers, our President, beginning in the year ended 12-31-19 through 9-30-21. During the quarter ended 9-30-21, the loans totaled $6,500.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3.1 June 24, 2021)	Page 4 of 9

1. Financial Statements

A. The following financial statements were prepared in accordance with:

1. ☒ U.S. GAAP ☐ IFRS

2. The financial statements for this reporting period were prepared by (name of individual)4:

Name:	Richard Moore
Title:	CPA
Relationship to Issuer:	Independent Certified Public Accountant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

1. Balance sheet;
2. Statement of income;
3. Statement of cash flows;
4. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
5. Financial notes; and
6. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Unaudited Financial Statements for the Quarterly periods ended 9/30/21 and 9/30/20 are being posted to OTC Markets, Inc. contemporaneously herewith, and are hereby incorporated by reference.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

1. Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

1. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations") No operations

4 The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3.1 June 24, 2021)	Page 5 of 9